Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04037527 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04037527: Clinical Trial Phase 1 study, sponsored by Wake Forest University Health Sciences.
NCT04037527 is a Phase 1 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04037527, a Phase 1 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this Phase 1 research study is to obtain data or information on the safety and effectiveness of the combination of gemcitabine, docetaxel with radiation.
Primary Outcome
Maximum tolerated dose of Gemcitabine and Taxotere and radiation will be completed by monitoring toxicities and using the 3+3 dose escalation plan.
Interventions
- DRUG Docetaxel
- PROCEDURE Surgical Resection
- DRUG Gemcitabine
- RADIATION Radiation
- OTHER Blood draws
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-08-18 |
| Est. Completion | 2024-06-18 |
| Phase | Phase 1 |
Why NCT04037527 stopped before completion
NCT04037527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT04037527 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04037527 about?
NCT04037527 is a clinical study titled "Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities". The purpose of this Phase 1 research study is to obtain data or information on the safety and effectiveness of the combination of gemcitabine, docetaxel with radiation.
What is the current status of trial NCT04037527?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2020-08-18. Estimated completion is 2024-06-18.
What interventions are being tested in trial NCT04037527?
The interventions under investigation include: Docetaxel (DRUG), Surgical Resection (PROCEDURE), Gemcitabine (DRUG), Radiation (RADIATION), Blood draws (OTHER).
Who is sponsoring clinical trial NCT04037527?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04037527's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI